Stock Market Reviews

GHRS (GH Research PLC) News

Get the latest news, insights, and market updates on GHRS (GH Research PLC). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Weekly Roundup on the Cannabis Sector & Psychedelic Sector
  Key Takeaways; Cannabis Sector Tilray Achieved Profitability with Record Revenue Growth Across Cannabis and Beverage Segments Organigram Launched a New Hemp-Derived THC Brand in the US Canopy Growth Converted DOJA Facility into a Dedicated Medical Cannabis Site Cronos Group announced expansion of its popular SOURZ by Spinach Gummies Key Takeaways; Psychedelic Sector GH Research Showcased […]
  Oct 13, 2025 - $GHRS
• GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
  DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 – 14, where Professor Wiesław J. Cubała, MD, PhD, Department of Psychiatry,
  Oct 9, 2025 - $GHRS
• GH Research PLC (GHRS) Reports 73% Remission in Phase 2b Depression Trial
  We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. GH Research PLC stands ninth among them. GH Research PLC (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company developing innovative therapies for treatment-resistant depression (TRD) and other psychiatric and neurological disorders. Its lead candidate, GH001, is an inhalable mebufotenin product currently in […]
  Sep 2, 2025 - $GHRS
• GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
  Global pivotal program initiation on track for 2026Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was well tolerated and no treatment related serious adverse events were reported. There was no evidence of treatment-emergent suicidal ideation or behaviorCash, cash equivalents and marketable securities of $308.7 million as of June 30,
  Aug 7, 2025 - $GHRS
• In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A
  A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelics.
  Jul 31, 2025 - $GHRS
• GH Research Announces Global Pivotal Program Plans and Further Development Updates
  Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was well tolerated and no treatment related serious adverse events were reported. There was no evidence of treatment-emergent suicidal ideation or behaviorGlobal pivotal program initiation on track for 2026 DUBLIN, July 23, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clin
  Jul 23, 2025 - $GHRS
• Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade
  The average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Jul 16, 2025 - $GHRS
• GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule
  GH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts. On June 20, GH Research announced that it had submitted a complete response to the US FDA regarding the clinical hold on its Investigational New Drug/IND Application for GH001. The submission was made ahead of schedule, which showed the company’s commitment to […]
  Jul 9, 2025 - $GHRS
• GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
  DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA). “We are thrilled to have submitted our response to the FDA a
  Jun 20, 2025 - $GHRS
• Trump Trade: President said to weigh possible U.S. strike against Iran
  Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: IRAN: U.S. President Donald Trump is weighing a range of potential actions in response to a recent armed conflict between Israel and Iran, including a possible U.S. strike against Iran, and met with top White House advisers to discuss the matter on Tuesday, the Wall Street Journal reports, citing
  Jun 19, 2025 - $GHRS